Exelixis, Inc. (0IJO.L)
USD 35.79
(3.5%)
USD 35.79
(3.5%)
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2023 | 1.83 Billion USD | 13.6% |
| 2022 | 1.61 Billion USD | 12.27% |
| 2021 | 1.43 Billion USD | 45.31% |
| 2020 | 987.53 Million USD | 2.04% |
| 2019 | 967.77 Million USD | 13.35% |
| 2018 | 853.82 Million USD | 88.7% |
| 2017 | 452.47 Million USD | 136.34% |
| 2016 | 191.45 Million USD | 415.05% |
| 2015 | 37.17 Million USD | 48.03% |
| 2014 | 25.11 Million USD | -19.87% |
| 2013 | 31.33 Million USD | -33.96% |
| 2012 | 47.45 Million USD | -83.62% |
| 2011 | 289.63 Million USD | 56.52% |
| 2010 | 185.04 Million USD | 21.93% |
| 2009 | 151.75 Million USD | 28.76% |
| 2008 | 117.85 Million USD | 3.87% |
| 2007 | 113.47 Million USD | 15.0% |
| 2006 | 98.67 Million USD | 29.9% |
| 2005 | 75.96 Million USD | 43.71% |
| 2004 | 52.85 Million USD | 2.56% |
| 2003 | 51.54 Million USD | 16.29% |
| 2002 | 44.32 Million USD | 8.09% |
| 2001 | 41 Million USD | 65.62% |
| 2000 | 24.75 Million USD | 135.8% |
| 1999 | 10.5 Million USD | 362.15% |
| 1998 | 2.27 Million USD | 0.0% |
| Year | Revenue | Revenue Growth |
|---|---|---|
| 2024 Q2 | 637.17 Million USD | 49.84% |
| 2024 Q3 | 478.05 Million USD | -15.32% |
| 2024 Q1 | 425.22 Million USD | -11.35% |
| 2023 FY | 1.83 Billion USD | 13.6% |
| 2023 Q3 | 471.92 Million USD | 0.44% |
| 2023 Q2 | 469.84 Million USD | 14.94% |
| 2023 Q1 | 408.78 Million USD | -3.57% |
| 2023 Q4 | 479.65 Million USD | 1.64% |
| 2022 Q2 | 419.42 Million USD | 17.82% |
| 2022 Q1 | 355.98 Million USD | -21.09% |
| 2022 Q3 | 411.73 Million USD | -1.83% |
| 2022 Q4 | 423.91 Million USD | 2.96% |
| 2022 FY | 1.61 Billion USD | 12.27% |
| 2021 FY | 1.43 Billion USD | 45.31% |
| 2021 Q1 | 270.23 Million USD | 0.07% |
| 2021 Q2 | 385.17 Million USD | 42.54% |
| 2021 Q4 | 451.14 Million USD | 37.37% |
| 2021 Q3 | 328.42 Million USD | -14.73% |
| 2020 Q2 | 259.47 Million USD | 14.35% |
| 2020 Q3 | 231.09 Million USD | -10.94% |
| 2020 Q4 | 270.05 Million USD | 16.86% |
| 2020 FY | 987.53 Million USD | 2.04% |
| 2020 Q1 | 226.91 Million USD | -5.57% |
| 2019 Q1 | 215.48 Million USD | -5.74% |
| 2019 FY | 967.77 Million USD | 13.35% |
| 2019 Q4 | 240.31 Million USD | -11.55% |
| 2019 Q3 | 271.7 Million USD | 13.08% |
| 2019 Q2 | 240.27 Million USD | 11.5% |
| 2018 Q1 | 212.34 Million USD | 76.85% |
| 2018 FY | 853.82 Million USD | 88.7% |
| 2018 Q4 | 228.6 Million USD | 1.42% |
| 2018 Q3 | 225.39 Million USD | 21.11% |
| 2018 Q2 | 186.1 Million USD | -12.36% |
| 2017 Q4 | 120.07 Million USD | -21.27% |
| 2017 Q1 | 80.88 Million USD | 4.26% |
| 2017 FY | 452.47 Million USD | 136.34% |
| 2017 Q3 | 152.51 Million USD | 54.04% |
| 2017 Q2 | 99 Million USD | 22.4% |
| 2016 Q3 | 62.19 Million USD | 71.56% |
| 2016 Q1 | 15.42 Million USD | 55.23% |
| 2016 FY | 191.45 Million USD | 415.05% |
| 2016 Q4 | 77.58 Million USD | 24.74% |
| 2016 Q2 | 36.25 Million USD | 134.99% |
| 2015 Q2 | 7.99 Million USD | -14.87% |
| 2015 FY | 37.17 Million USD | 48.03% |
| 2015 Q4 | 9.93 Million USD | 0.85% |
| 2015 Q3 | 9.85 Million USD | 23.3% |
| 2015 Q1 | 9.38 Million USD | 27.68% |
| 2014 FY | 25.11 Million USD | -19.87% |
| 2014 Q4 | 7.35 Million USD | 16.88% |
| 2014 Q3 | 6.29 Million USD | -4.13% |
| 2014 Q2 | 6.56 Million USD | 33.78% |
| 2014 Q1 | 4.9 Million USD | 12.84% |
| 2013 FY | 31.33 Million USD | -33.96% |
| 2013 Q4 | 4.34 Million USD | -20.47% |
| 2013 Q3 | 5.46 Million USD | -53.9% |
| 2013 Q2 | 11.85 Million USD | 22.62% |
| 2013 Q1 | 9.66 Million USD | 23.74% |
| 2012 Q4 | 7.81 Million USD | -41.31% |
| 2012 FY | 47.45 Million USD | -83.62% |
| 2012 Q1 | 18.51 Million USD | -80.16% |
| 2012 Q2 | 7.81 Million USD | -57.79% |
| 2012 Q3 | 13.31 Million USD | 70.4% |
| 2011 Q4 | 93.3 Million USD | -27.26% |
| 2011 FY | 289.63 Million USD | 56.52% |
| 2011 Q3 | 128.27 Million USD | 298.83% |
| 2011 Q2 | 32.16 Million USD | -10.39% |
| 2011 Q1 | 35.89 Million USD | -11.98% |
| 2010 Q2 | 47.59 Million USD | 12.79% |
| 2010 Q4 | 40.77 Million USD | -25.15% |
| 2010 Q3 | 54.47 Million USD | 14.45% |
| 2010 Q1 | 42.19 Million USD | -4.26% |
| 2010 FY | 185.04 Million USD | 21.93% |
| 2009 Q1 | 25.3 Million USD | -14.44% |
| 2009 Q4 | 44.07 Million USD | -19.82% |
| 2009 Q3 | 54.97 Million USD | 100.63% |
| 2009 Q2 | 27.4 Million USD | 8.3% |
| 2009 FY | 151.75 Million USD | 28.76% |
| 2008 Q2 | 30.41 Million USD | 8.83% |
| 2008 Q1 | 27.94 Million USD | -4.46% |
| 2008 FY | 117.85 Million USD | 3.87% |
| 2008 Q4 | 29.57 Million USD | -1.2% |
| 2008 Q3 | 29.93 Million USD | -1.58% |
| 2007 Q4 | 29.25 Million USD | 9.04% |
| 2007 Q2 | 29.25 Million USD | 3.99% |
| 2007 Q1 | 28.13 Million USD | -5.49% |
| 2007 FY | 113.47 Million USD | 15.0% |
| 2007 Q3 | 26.82 Million USD | -8.32% |
| 2006 Q1 | 18.11 Million USD | 26.03% |
| 2006 Q4 | 29.77 Million USD | 26.47% |
| 2006 Q3 | 23.54 Million USD | -13.58% |
| 2006 Q2 | 27.24 Million USD | 50.34% |
| 2006 FY | 98.67 Million USD | 29.9% |
| 2005 Q3 | 14.4 Million USD | -58.03% |
| 2005 Q1 | 12.87 Million USD | -18.23% |
| 2005 Q4 | 14.37 Million USD | -0.16% |
| 2005 FY | 75.96 Million USD | 43.71% |
| 2005 Q2 | 34.31 Million USD | 166.51% |
| 2004 Q3 | 12.66 Million USD | 0.82% |
| 2004 Q2 | 12.55 Million USD | 5.61% |
| 2004 FY | 52.85 Million USD | 2.56% |
| 2004 Q1 | 11.89 Million USD | -13.61% |
| 2004 Q4 | 15.74 Million USD | 24.34% |
| 2003 Q1 | 12.33 Million USD | -0.99% |
| 2003 Q2 | 13 Million USD | 5.47% |
| 2003 Q3 | 12.43 Million USD | -4.35% |
| 2003 FY | 51.54 Million USD | 16.29% |
| 2003 Q4 | 13.76 Million USD | 10.67% |
| 2002 Q1 | 11.56 Million USD | -9.64% |
| 2002 Q4 | 12.45 Million USD | 19.4% |
| 2002 FY | 44.32 Million USD | 8.09% |
| 2002 Q3 | 10.43 Million USD | 5.39% |
| 2002 Q2 | 9.89 Million USD | -14.39% |
| 2001 Q3 | 11.92 Million USD | 39.49% |
| 2001 Q2 | 8.55 Million USD | 10.56% |
| 2001 Q1 | 7.73 Million USD | 9.33% |
| 2001 Q4 | 12.79 Million USD | 7.25% |
| 2001 FY | 41 Million USD | 65.62% |
| 2000 Q4 | 7.07 Million USD | 15.63% |
| 2000 Q1 | 5.95 Million USD | 0.0% |
| 2000 Q2 | 5.61 Million USD | -5.63% |
| 2000 FY | 24.75 Million USD | 135.8% |
| 2000 Q3 | 6.11 Million USD | 8.94% |
| 1999 FY | 10.5 Million USD | 362.15% |
| 1998 FY | 2.27 Million USD | 0.0% |
| Name | Revenue | Revenue Difference |
|---|---|---|
| Thermo Fisher Scientific Inc. | 42.85 Billion USD | 95.73% |
| Dynavax Technologies Corporation | 232.28 Million USD | -687.918% |
| Illumina, Inc. | 4.5 Billion USD | 59.365% |
| IQVIA Holdings Inc. | 14.98 Billion USD | 87.786% |
| Biogen Inc. | 9.83 Billion USD | 81.392% |
| Iovance Biotherapeutics, Inc. | 1.18 Million USD | -153828.343% |
| Mettler-Toledo International Inc. | 3.78 Billion USD | 51.688% |
| Sarepta Therapeutics, Inc. | 1.24 Billion USD | -47.201% |
| Supernus Pharmaceuticals, Inc. | 607.52 Million USD | -201.258% |
| Waters Corporation | 2.95 Billion USD | 38.094% |
| Perrigo Company plc | 4.65 Billion USD | 60.688% |
| uniQure N.V. | 15.84 Million USD | -11452.156% |
| Agios Pharmaceuticals, Inc. | 26.82 Million USD | -6723.279% |
| Amicus Therapeutics, Inc. | 399.35 Million USD | -358.29% |
| Atara Biotherapeutics, Inc. | 8.57 Million USD | -21248.513% |
| bluebird bio, Inc. | 29.49 Million USD | -6104.726% |
| Cara Therapeutics, Inc. | 20.96 Million USD | -8628.577% |
| Imunon, Inc. | - USD | -Infinity% |
| Myriad Genetics, Inc. | 678.4 Million USD | -169.783% |
| Neurocrine Biosciences, Inc. | 1.88 Billion USD | 3.015% |
| Nektar Therapeutics | 90.12 Million USD | -1930.812% |
| Editas Medicine, Inc. | 78.12 Million USD | -2242.726% |
| Verastem, Inc. | - USD | -Infinity% |
| Walgreens Boots Alliance, Inc. | 147.65 Billion USD | 98.761% |
| Corbus Pharmaceuticals Holdings, Inc. | - USD | -Infinity% |
| Heron Therapeutics, Inc. | 127.04 Million USD | -1340.61% |
| Unity Biotechnology, Inc. | - USD | -Infinity% |
| BioMarin Pharmaceutical Inc. | 2.41 Billion USD | 24.347% |
| Sangamo Therapeutics, Inc. | 176.23 Million USD | -938.522% |
| Evolus, Inc. | 202.08 Million USD | -805.662% |
| Adicet Bio, Inc. | - USD | -Infinity% |
| Aclaris Therapeutics, Inc. | 31.24 Million USD | -5756.853% |
| Regeneron Pharmaceuticals, Inc. | 13.11 Billion USD | 86.047% |
| Esperion Therapeutics, Inc. | 116.33 Million USD | -1473.236% |
| FibroGen, Inc. | 147.75 Million USD | -1138.703% |
| Agilent Technologies, Inc. | 6.83 Billion USD | 73.215% |
| OPKO Health, Inc. | 863.49 Million USD | -111.954% |
| Homology Medicines, Inc. | -6.65 Million USD | 27617.787% |
| Geron Corporation | 237 Thousand USD | -772139.662% |
| Alnylam Pharmaceuticals, Inc. | 1.82 Billion USD | -0.105% |
| Viking Therapeutics, Inc. | - USD | -Infinity% |
| Anavex Life Sciences Corp. | - USD | -Infinity% |
| Intellia Therapeutics, Inc. | 36.27 Million USD | -4945.37% |
| Zoetis Inc. | 8.54 Billion USD | 78.579% |
| Axsome Therapeutics, Inc. | 270.6 Million USD | -576.352% |
| Abeona Therapeutics Inc. | 3.5 Million USD | -52191.657% |
| Vertex Pharmaceuticals Incorporated | 9.86 Billion USD | 81.455% |
| Kala Pharmaceuticals, Inc. | - USD | -Infinity% |
| Ionis Pharmaceuticals, Inc. | 787.64 Million USD | -132.364% |
| Corcept Therapeutics Incorporated | 482.37 Million USD | -279.416% |
| Halozyme Therapeutics, Inc. | 829.25 Million USD | -120.706% |
| Blueprint Medicines Corporation | 249.38 Million USD | -633.903% |
| Insmed Incorporated | 305.2 Million USD | -499.659% |
| TG Therapeutics, Inc. | 233.66 Million USD | -683.272% |
| Incyte Corporation | 3.69 Billion USD | 50.477% |
| Emergent BioSolutions Inc. | 1.04 Billion USD | -74.422% |